Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (874)	6/23/2001 10:17:00 AM
From: 2MAR$	Respond to of 208838

Which is a better short sale, BGEN, XOMA or DNA? TIA I am never sure about anything , when it comes to the BIO's . Some of those valuations just defy gravity and are like buying EBAY long for $500/shr <gg> Then you have LEHM(?) issuing targets of $80 on GENE ? Just invitations to short, IMO. Did you catch BGEN short friday ? Combined with the early morning premarket warning for MRK , and the recent run-ups for PDLI , seemed early morning weakness was a sign to jump in and pounce early . If I had been following BGEN more closely and that chain of events , I would have been shorting a ton more BGEN friday morning...not good when a company seems to change the tone of their results from good to bad in just a day ...investors kind of frown on switching numbers and indicators overnight .... BGEN doesn't sport that high a PE (35 approx) compared to DNA's (somewhere near 600?), XOMA lacks something normally valuable to most companies called ------> revenues... XOMA fundies (from marketguide): BRIEF: XOMA develops and manufactures antibody and other protein biopharmaceuticals for disease targets that include immunological and inflammatory disorders, infectious diseases and cancer. For the 3 months ended 3/31/01, revenues rose 11% to $2.9M. Net loss increased 21% to $7.6M. Results reflect the recognition of certain license and other fee payments received from Baxter and Onyx, offset by increased product development expenses. * I was thinking BGEN was short around $60 before , just because of major decreasing net-revs & their pressing need to get new drugs in the pipeline as older drug patents expire.... something all pharmies experience. But many (not AFFX MDCC) bios had been bidding up recently , so I just watched from a safe distance, waiting for some negative/positive developement. I wish BGEN well, but I am a trader too , and wouldn't have wanted to go long with this last report: BGEN's fundies: BRIEF: BGEN is a biopharmaceutical company primarily engaged in the business of developing, manufacturing and marketing drugs for human health care. BGEN currently derives revenues from sales of AVONEX and from royalties on worldwide sales by licensees. For the 3 months ended 3/01, total revenues rose 9% to $237M. Net income decreased 41% to $72.1M. Results reflect an increase in the sales volume of AVONEX, offset by decreased gains on securities. stockcharts.com[m,a]daclyymy[pb50!b200][vc60][iUb14!La12,26,9] not the greatest looking chart ...